
Agenus Inc. (&#34;Agenus&#34;) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026.


Agenus plans

<p xmlns="http://www.w3.org/1999/xhtml">
<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com&amp;esheet=54528584&amp;newsitemid=20260504196835&amp;lan=en-US&amp;anchor=Agenus+Inc&amp;index=1&amp;md5=c0ed73fb8f59d8ca436f059ba2d9f4af" shape="rect"><b xmlns="http://www.w3.org/1999/xhtml">Agenus Inc</b></a><b xmlns="http://www.w3.org/1999/xhtml">.</b> ("Agenus") (Nasdaq: <b xmlns="http://www.w3.org/1999/xhtml">AGEN</b>), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Agenus plans to host a webcast in June, in conjunction with its Annual Meeting of Shareholders, to spotlight key strategic priorities, upcoming data milestones, and progress across the global botensilimab (BOT) and balstilimab (BAL) development program.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Agenus</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com&amp;esheet=54528584&amp;newsitemid=20260504196835&amp;lan=en-US&amp;anchor=www.agenusbio.com&amp;index=2&amp;md5=ed3eefb5b84717bbacf26efe160ed7b8" shape="rect">www.agenusbio.com</a> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Botensilimab (BOT)</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=54528584&amp;newsitemid=20260504196835&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=3&amp;md5=94e98f23a711477955aa42119ac65273" shape="rect">www.clinicaltrials.gov</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Balstilimab (BAL)</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words &#34;may,&#34; &#34;believes,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;hopes,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;forecasts,&#34; &#34;estimates,&#34; &#34;will,&#34; "establish," "potential," "superiority," "best in class," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Source: Agenus Bio</b>

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260504196835r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260504196835/en/" rel="nofollow">https://www.businesswire.com/news/home/20260504196835/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
Investors : 917-362-1370 &#x7C; <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:investor@agenusbio.com" shape="rect">investor@agenusbio.com 
</a><br xmlns="http://www.w3.org/1999/xhtml"></br>Media: 781-674-4422 &#x7C; <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:communications@agenusbio.com" shape="rect">communications@agenusbio.com</a>

</p>

AGEN

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus to Release Q1 2026 Results and Host Webcast in June

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Agenus Inc. (&amp;#34;Agenus&amp;#34;) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026.


Agenus plans</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Agenus is set to announce its Q1 2026 financial results on May 11, 2026. The subsequent webcast will outline the company’s strategic focus and progress on its botensilimab and balstilimab programs, which could lead to increased investor interest and potential stock movement.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Agenus will announce Q1 2026 financial results on May 11, 2026.</li><li>Agenus to host a shareholder meeting webcast in June 2026.</li><li>Focus on strategic priorities and updates on botensilimab and balstilimab.</li><li>Botensilimab shows clinical responses in late-line cancers with 1,200 patients treated.</li><li>Balstilimab has been evaluated in over 900 patients with favorable results.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>MiNK Therapeutics (MINK)</strong>: Key partner in cell therapies but no direct financial updates.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as it reveals upcoming financial guidance and strategic initiatives that could impact share performance and investor perceptions in the immuno-oncology sector.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Q1 2026 financial performance could influence stock sentiment significantly.</li><li>Strategic details unveiled in the June webcast may attract new investors.</li><li>Positive developments in botensilimab and balstilimab trials can boost share price.</li><li>Investor anticipation of upcoming data milestones is likely to enhance market activity.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q1 2026 results to be released on May 11, 2026.</li><li>Agenus will host a webcast in June for shareholders.</li><li>Botensilimab has shown clinical responses across nine cancers in trials.</li><li>Over 1,200 patients treated with botensilimab and balstilimab.</li><li>Balstilimab evaluated in more than 900 patients to date.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Agenus is a buy ahead of financial results and strategic updates by June.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com&amp;esheet=54528584&amp;newsitemid=20260504196835&amp;lan=en-US&amp;anchor=Agenus+Inc&amp;index=1&amp;md5=c0ed73fb8f59d8ca436f059ba2d9f4af" shape="rect"><b xmlns="http://www.w3.org/1999/xhtml">Agenus Inc</b></a><b xmlns="http://www.w3.org/1999/xhtml">.</b> ("Agenus") (Nasdaq: <b xmlns="http://www.w3.org/1999/xhtml">AGEN</b>), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Agenus plans to host a webcast in June, in conjunction with its Annual Meeting of Shareholders, to spotlight key strategic priorities, upcoming data milestones, and progress across the global botensilimab (BOT) and balstilimab (BAL) development program.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Agenus</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com&amp;esheet=54528584&amp;newsitemid=20260504196835&amp;lan=en-US&amp;anchor=www.agenusbio.com&amp;index=2&amp;md5=ed3eefb5b84717bbacf26efe160ed7b8" shape="rect">www.agenusbio.com</a> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Botensilimab (BOT)</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=54528584&amp;newsitemid=20260504196835&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=3&amp;md5=94e98f23a711477955aa42119ac65273" shape="rect">www.clinicaltrials.gov</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Balstilimab (BAL)</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words &#34;may,&#34; &#34;believes,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;hopes,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;forecasts,&#34; &#34;estimates,&#34; &#34;will,&#34; "establish," "potential," "superiority," "best in class," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Source: Agenus Bio</b>

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260504196835r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260504196835/en/" rel="nofollow">https://www.businesswire.com/news/home/20260504196835/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
Investors : 917-362-1370 &#x7C; <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:investor@agenusbio.com" shape="rect">investor@agenusbio.com 
</a><br xmlns="http://www.w3.org/1999/xhtml"></br>Media: 781-674-4422 &#x7C; <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:communications@agenusbio.com" shape="rect">communications@agenusbio.com</a>

</p>

Agenus is set to announce its Q1 2026 financial results on May 11, 2026. The subsequent webcast will outline the company’s strategic focus and progress on its botensilimab and balstilimab programs, which could lead to increased investor interest and potential stock movement.

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News